Spire Healthcare has agreed a 250p-a-share cash offer from a Toscafund-led consortium, while its delayed half-year figures showed stable Revenue but a swing to a pre-tax loss as NHS work declined.

Spire Healthcare (LSE:SPI), the largest independent hospital operator in the UK, looks set to leave the FTSE 250 after its board backed a Takeover from a consortium led by its long-standing Shareholder Toscafund. The deal, agreed in early September after months of negotiation, was followed on 30 September by delayed interim results that underlined both the resilience of private Demand and the pressure from lower NHS volumes.

The offer

On 7 September, Spire announced that it had agreed a cash offer of 250p per share from Tulip UK Bidco, a vehicle backed by Toscafund Asset Management, London buyout firm Three Hills and US Investment manager Ares Management. The bid values the company at roughly £1.03bn and represents a premium of about 66% to the share price on 13 May 2026, before the approach became public.

The agreement brought to an end a lengthy put-up-or-shut-up process, during which the deadline for a firm offer was extended several times. Toscafund, which held an 18.1% stake in March, had already completed Due Diligence by August. Interim chair Debbie White said the 250p offer was higher than all other formal proposals received during the process and gave shareholders certain value in cash today.

Leadership change

The deal coincided with a reshaping of the top team. Chief executive Justin Ash stepped down, with David Sloman taking the role on an interim basis, while chair Ian Cheshire retired and Debbie White became interim chair. Paolo Pieri, the former chief executive of Circle Health Group, is lined up to chair the Business after completion.

Half-year figures

Spire's results for the six months to 30 June, originally due on 9 September, showed revenue edging down 0.5% to £792.7m. NHS revenue fell 14%, with a 25% drop in the first quarter easing to a 3% decline in the second. Growth in private medical insurance, self-pay and primary care partly offset that shortfall. The group swung to a pre-tax loss of £14.8m, compared with a profit of £10.8m a year earlier, and no Interim Dividend was declared.

Management kept its full-year guidance for adjusted EBITDA broadly in line with the prior year's level of around £268.6m. It also said visibility over NHS activity was healthy, with more than 95% of revenue linked to indicative activity plans for the 2026/27 NHS financial year already secured.

Sector context

The independent sector has had a mixed year. Elective recovery funding and NHS waiting lists continue to support demand, but local commissioning decisions and budget pressures caused a sharp dip in referrals earlier in 2026. Private medical insurance has been a bright spot as more employers offer cover, while self-pay patients remain sensitive to household finances.

What happens next

With the offer backed by the board, attention shifts to the formal timetable: the publication of the scheme document, shareholder meetings and any regulatory approvals. Shares in such situations typically trade close to, but slightly below, the Offer Price until completion, reflecting the time value and deal risk. Should the transaction proceed, Spire would delist from the London Stock Exchange and leave the FTSE 250.